The fund is rated 0.5 stars. Investment selection within each industry provided some support. Investment selection within each asset type and balance between returns and downside risk were the main limitations and did not provide enough support for a higher rating. Higher annual fee of 2.12% and above-average fund size of Rs 3,501.37 crore were minor drawbacks.
This fund has a bad track record with Asset Selection/Timing, a ok track record with Stock Selection/Timing, a bad risk-reward ratio. It is important to note, however, that this fund has a 3501.368 AUM and a 2.12 expense ratio. Considering all these factors, we have rated this fund as 0.5 star.
हमारा स्कोर दीर्घकालिक प्रदर्शन, जोखिम और निरंतरता को तौलता है — केवल पिछले रिटर्न को नहीं।
5 Nov 2026 तक
31 Oct 2026 तक
30 Sep 2026 तक
| होल्डिंग | फंड का % | मूल्य | शेयर |
|---|---|---|---|
| Divi's Laboratories Ltd. | 9.39% | ₹328.63 Cr | 3,53,687 |
| Sun Pharmaceutical Industries Ltd. | 8.28% | ₹289.76 Cr | 15,95,093 |
| Others | 4.67% | ₹163.43 Cr | — |
| Alkem Laboratories Ltd. | 4.64% | ₹162.58 Cr | 3,14,859 |
| Cipla Ltd. | 4.15% | ₹145.37 Cr | 10,80,050 |
| Apollo Hospitals Enterprise Ltd. | 3.69% | ₹129.18 Cr | 1,58,200 |
| Torrent Pharmaceuticals Ltd. | 3.65% | ₹127.91 Cr | 2,66,486 |
| Max Healthcare Institute Ltd. | 3.61% | ₹126.42 Cr | 13,59,696 |
| Aster DM Quality Care Ltd. | 3.56% | ₹124.51 Cr | 17,86,027 |
| Lupin Ltd. | 3.55% | ₹124.15 Cr | 6,11,505 |
To generate long-term capital appreciation Investment predominantly in equity & equity related instruments of Pharma and healthcare companies.
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Exit load of 1%, if redeemed within 30 days.
म्यूचुअल फंड बाज़ार जोखिम के अधीन हैं। सभी योजना दस्तावेज़ ध्यानपूर्वक पढ़ें।
